Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 3:58 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 466 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: breast biopsy Clear all
Completed No phase listed Observational

Nodal Burden and Nodal Recurrence in Patients With Isolated Tumor Cells After Neoadjuvant Chemotherapy Treated With Axillary Dissection or Nodal Radiation: the OPBC-05/EUBREAST-14R/ICARO Study

NCT06464341
View directory record Official record
Conditions
Breast Cancer
Interventions
Observational study no intervention
Other
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
583 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Los Angeles, California • Miami, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 2, 2026, 3:58 AM EDT
Recruiting Not applicable Interventional

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

NCT05890677
View directory record Official record
Conditions
Lymphedema, Breast Cancer
Interventions
Surgical Intervention, Conservative Complex Physical Decongestion Therapy
Procedure
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Sep 2, 2026, 3:58 AM EDT
Active, not recruiting No phase listed Observational

Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation

NCT04854005
View directory record Official record
Conditions
Breast Cancer
Interventions
Breast surgery
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
10
States / cities
Hartford, Connecticut • Ann Arbor, Michigan • Basking Ridge, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2026 · Synced Sep 2, 2026, 3:58 AM EDT
Not listed Not applicable Interventional

An Evaluation of a Self-contained Direct Digital Radiography System for Breast Specimen Imaging

NCT01379092
View directory record Official record
Conditions
Breast Cancer
Interventions
Trident Specimen Radiography System, Bioptics, Faxitron, and Full Field Digital Mammography (FFDM) Selenia
Device
Lead sponsor
Levine, Gary M. , M.D.
Individual
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Sep 2, 2026, 3:58 AM EDT
Active, not recruiting Not applicable Interventional

Nature Sounds as a Pain and Anxiety Reducing Strategy in Patients Undergoing Breast Core Biopsy

NCT03238976
View directory record Official record
Conditions
Breast Cancer
Interventions
Nature sounds
Other
Lead sponsor
University of Chicago
Other
Eligibility
21 Years and older · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Sep 2, 2026, 3:58 AM EDT
Terminated No phase listed Observational

Clinical Evaluation of OSNA Breast Cancer System in Breast Cancer Patients Receiving Neoadjuvant Therapy

NCT01140776
View directory record Official record
Conditions
Breast Neoplasms, Breast Diseases
Interventions
Not listed
Lead sponsor
Sysmex America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
2
States / cities
Tucson, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Sep 2, 2026, 3:58 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Feasibility of One-Step Sentinel Lymph Node (SLN) Biopsy With Radiolabeled Methylene Blue (IND 70,627)

NCT00784849
View directory record Official record
Conditions
Breast Cancer
Interventions
Methylene blue
Drug
Lead sponsor
Louisiana State University Health Sciences Center in New Orleans
Other
Eligibility
18 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
2
States / cities
Lafayette, Louisiana • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 19, 2012 · Synced Sep 2, 2026, 3:58 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Real-time Intraoperative Breast Cancer Visualization for Margin Assessment

NCT02807597
View directory record Official record
Conditions
Breast Cancer, Cancer of the Breast
Interventions
LS301, Cancer Vision Goggles and standard fluorescence imaging systems, Surgery
Drug · Device · Procedure
Lead sponsor
Samuel Achilefu
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 16, 2025 · Synced Sep 2, 2026, 3:58 AM EDT
Terminated No phase listed Observational Results available

Gene Expression in Tumor Tissue From Women Undergoing Surgery for Breast Cancer or Core Biopsy of the Breast

NCT00898937
View directory record Official record
Conditions
Breast Cancer
Interventions
microarray analysis, breast biopsy
Genetic · Procedure
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Sep 2, 2026, 3:58 AM EDT
Terminated Not applicable Interventional Results available

Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT)

NCT02324205
View directory record Official record
Conditions
Breast Cancer, Tumors, Breast
Interventions
DBT and FFDM
Device
Lead sponsor
GE Healthcare
Industry
Eligibility
30 Years and older · Female only
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Boca Raton, Florida • Voorhees Township, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 2, 2026, 3:58 AM EDT
Completed Phase 2 Interventional Results available

Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer

NCT03747042
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Letrozole
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 2, 2026, 3:58 AM EDT
Terminated Phase 1 Interventional

Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

NCT03128619
View directory record Official record
Conditions
Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Postmenopausal, Progesterone Receptor Positive, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Biopsy of Breast, Copanlisib, Laboratory Biomarker Analysis, Letrozole, Palbociclib, Pharmacological Study
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced Sep 2, 2026, 3:58 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

ZTE MRI Pulse Sequence Use for Visualization of Bone Cement, Breast Biopsy Markers

NCT06873802
View directory record Official record
Conditions
Breast Carcinoma
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 8, 2025 · Synced Sep 2, 2026, 3:58 AM EDT
Withdrawn Phase 1 Interventional

Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer

NCT02619669
View directory record Official record
Conditions
Breast Cancer
Interventions
TAK-228, Letrozole
Drug
Lead sponsor
Gary Schwartz
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 2, 2026, 3:58 AM EDT
Terminated Phase 2 Interventional Results available

Preoperative Palbociclib in Patients With DCIS of the Breast That Are Candidates for Surgery

NCT03535506
View directory record Official record
Conditions
DCIS
Interventions
Palbociclib
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Sep 2, 2026, 3:58 AM EDT
Completed Phase 1Phase 2 Interventional

NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)

NCT00248404
View directory record Official record
Conditions
Tumors
Interventions
NB1011
Drug
Lead sponsor
Kiadis Pharma
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Los Angeles, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 15, 2022 · Synced Sep 2, 2026, 3:58 AM EDT
Terminated No phase listed Observational

Developing Plasma DNA as a Surrogate for Tumor Biopsy to Identify Tumor Genetic Alterations in Patients With Advanced Breast Cancer

NCT01836640
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Not listed
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Sep 2, 2026, 3:58 AM EDT
Recruiting No phase listed Observational

SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

NCT05935384
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Colorectal Cancer, Breast Cancer
Interventions
Guardant360
Diagnostic Test
Lead sponsor
Guardant Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Skokie, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 2, 2026, 3:58 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

NCT06136897
View directory record Official record
Conditions
Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Biospecimen Collection, Echocardiography Test, Pertuzumab, Radiologic Examination, Trastuzumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 2, 2026, 3:58 AM EDT
Recruiting Phase 2 Interventional

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

NCT06184750
View directory record Official record
Conditions
Breast Atypical Ductal Hyperplasia, Breast Atypical Lobular Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Estrogen Receptor-Positive Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Mammography, Questionnaire Administration, Tamoxifen
Procedure · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 55 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
11
States / cities
Tucson, Arizona • Chicago, Illinois • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 2, 2026, 3:58 AM EDT
Terminated Phase 2 Interventional Results available

AMTEC IIT: Phase 2 Multiarm Study in TNBC

NCT03801369
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
Interventions
Biopsy, Capivasertib, Ceralasertib, Durvalumab, Olaparib, Quality-of-Life Assessment, Selumetinib
Procedure · Drug · Biological + 1 more
Lead sponsor
Gordon Mills, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Sep 2, 2026, 3:58 AM EDT
Recruiting No phase listed Observational

PAS 1ml Magtrace® for Sentinel Lymph Node Biopsy in Breast Cancer Patients

NCT06610539
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Endomagnetics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 2, 2026, 3:58 AM EDT
Recruiting Phase 1 Interventional

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

NCT05111561
View directory record Official record
Conditions
Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
Interventions
BET Bromodomain Inhibitor ZEN-3694, Binimetinib, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Galveston, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2026 · Synced Sep 2, 2026, 3:58 AM EDT
Completed Phase 2 Interventional

Axillary Reverse Mapping

NCT01381315
View directory record Official record
Conditions
Breast Cancer
Interventions
Injection of isotope, Axillary lymph node dissection
Procedure
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Sep 2, 2026, 3:58 AM EDT